Popular Articles
Cellulite Cream

Arena Pharmaceuticals Announces The Presentation Of Lorcaserin Phase 3 BLOOM Data At The American Diabetes Association's 69th Scientific Sessions
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial has been accepted for a poster presentation at the American Diabetes Association"s 69th Scientific Sessions in New Orleans, Louisiana. The abstract, titled "Lorcaserin Reduces Body Weight in Obese and Overweight Subjects: Behavioral Modification and Lorcaserin for Overweight and Obesity Management, the BLOOM Trial," will be displayed from June 6, 2009 at 10:00 a.m. Central Daylight Time (CDT) until June 8, 2009 at 4:00 p.m. CDT in the Morial Convention Center, Hall E. The poster has been assigned presentation number 96-LB in category 20-B Obesity - Clinical Treatment.
generic viagra online
Country GP Uses Household Drill To Save Boyò€¦and Shows Why Helicopters Cannot Replace Local Doctors, Australia
The Rural Doctors Association of Australia (RDAA) says two country doctors" skills last Friday-in saving
News of the day
VA Medical Imaging Reaches Record Level
VistA Imaging, the medical and health care imaging system used in Department of Veterans Affairs (VA) medical centers, attained over one billion stored images in January this year, according to the department.
Endocrinology

U.S. To Commit Additional $1B To H1N1 Vaccine Development

HHS Secretary Kathleen Sebelius said Sunday the U.S. has agreed to put an addition $1 billion towards ingredients for the production of a vaccine that offers protection against the H1N1 (swine flu) virus, Reuters reports. "There"ll be another $1 billion worth of orders placed to get the bulk ingredients for an H1N1 vaccination. Congress has agreed with the president that this is the number one priority, keeping Americans safe and secure," Sebelius said (7/12). The AFP/France24 writes: "[Sebelius"] remarks came as the Centers for Disease Control and Prevention confirmed 211 U.S. deaths from the A(H1N1) virus, with some 37,000 cases confirmed -the highest level of death and infection of any country in the world" (AFP/France24, 7/12). "[The] FDA is working with the scientists at NIH (National Institutes of Health) to make sure that we have a safe and effective strain and then we"re getting ready to make sure that we have a vaccination program," according to Sebelius. The FDA has scheduled a meeting to discuss the results of ongoing clinical trials of H1N1 vaccines for July 23; the Advisory Committee on Immunization Practice will convene on July 29, according to Reuters (7/12). Vaccine Makers Having Difficulty Producing H1N1 Vaccine; WHO Vaccine Recommendations Expected Monday The Canadian Press/Google.com writes, that "vaccine production has hit a snag, with manufacturers reporting a disappointingly low yield when vaccines viruses are grown in eggs." Marie-Paule Kieny, director of the WHO"s vaccine research initiative, said new seed strains are being created in the hope of boosting the vaccine yield. If yields cannot be increased, the vaccine production process will be slowed leading to pipeline delays for countries that have pre-ordered the vaccine. "And countries that haven"t pre-ordered pandemic vaccine would face substantial delays before manufacturers have product to sell to them," writes Canadian Press/Google.com (Branswell, 7/12). Meanwhile, a WHO spokeswoman said Friday that the WHO will likely issue its H1N1 vaccine recommendations Monday, Reuters/Ottawa Citizen reports (MacInnis/Nebehay, 7/10). H1N1 Spreads In Southern Africa, Countries Take Precautionary Measures To Stop H1N1 Spread During, After Hajj IRIN reports on the first confirmed cases of H1N1 in Botswana and Zimbabwe and the growing number of cases of H1N1 in South Africa. The article features an interview with the head of epidemiology at South Africa"s National Institute for Communicable Diseases, who characterized most of the H1N1 cases in the region as "mild", explaining "it was too early to tell whether people living with HIV/AIDS would be affected to a greater degree by the flu," IRIN writes (7/10). A separate IRIN article explores the precautionary efforts countries in the Middle East are taking to reduce the transmission of H1N1 during and after the 2009 Hajj pilgrimage which starts in late November (7/12). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):